More About Office of Technology Development Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

SK-MES-1: Lung Cancer Cell Line

SK2009-091

Description

SK-MES-1 is a human lung cancer cell line that displays epithelial morphology and grows as monolayers in tissue culture. These cells exhibit a cytokeratin expression pattern typical of simple epithelia (i.e., CK7, CK8, CK18, and CK19), and similar to that found in adenocarcinomas. In addition, the expression of Lamins A, B, and C is readily detected in these cells. The SK-MES-1 cells are known to form tumors in immunocompromised mice.

Source

This cell line was established in 1970 from a metastatic site (pleural effusion) in a 65-year-old Caucasian male with squamous cell carcinoma of the lung.

Inventors

  • Lloyd J. Old, MD, former William E. Snee Chair in Cancer Immunology, Memorial Sloan Kettering; former Director, New York Branch, Ludwig Institute for Cancer Research
  • Germain Trempe, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

Key References

  • Fogh J et al. (1977) Absence of HeLa cell contamination in 169 cell lines derived from human tumors. Journal of the National Cancer Institute 58: 209-214 (PubMed ID: 833871)
  • Blobel GA et al. (1984) Cytokeratins in normal lung and lung carcinomas. I. Adenocarcinomas, squamous cell carcinomas and cultured cell lines. Virchows Archiv, Cell Pathology Including Molecular Pathology. 45:407-29 (PubMed ID: 6203212)

Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

Contact information

  • For licensing requests: Alexandra Buga, MBA, Business Development Analyst, Office of Technology Development, MSK, 646-888-1078, bugaa@mskcc.org
  • For non-licensing requests from academic-research institutions: Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, weisgarf@mskcc.org

Stage of Development

Ready to use

Indications